ABSTRACT
The objective of this study was to evaluate the use of an extracorporeal immunomodulatory device on the immune dysregulated state of chronic heart failure (CHF). Inflammation has been associated with progression and complications of CHF but no effective therapy has yet been identified to treat this dysregulated immunologic state. The selective cytopheretic device (SCD) provides extracorporeal autologous cell processing to lessen the inflammatory activity of circulating leukocytes of the innate immunologic system. SCD treatment in a canine model of systolic CHF diminished leukocyte inflammatory activity and enhanced cardiac performance as measured by left ventricular (LV) ejection fraction and myocardial contractility by stroke volume (SV) up to 4 weeks after treatment initiation. Translation of these observations in first in human, proof of concept clinical study was evaluated in a patient with severe systolic CHF ineligible for cardiac transplantation or left ventricular assist device (LVAD) due to renal insufficiency and right ventricular dysfunction. Six hour SCD treatments over 6 consecutive days resulted in selective removal of inflammatory neutrophils and monocytes and reduction in key plasma cytokines, including tumor necrosis factor (TNF)-a, interleukin (IL)-6, IL-8, monocyte chemoattractant protein (MCP)-1. These immunologic changes were associated with significant improvements in cardiac power output, right ventricular stroke work index, cardiac index and LVSV index, stabilization of renal function with progressive volume removal permitted successful LVAD implantation. This translational research study demonstrates a promising immunomodulatory approach to improve cardiac performance in systolic CHF and supports the important role of inflammation in the progression of CHF.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: HDH, DAB, AJW: Innovative Biotherapies, Inc. and SeaStar Medical, Inc.
Clinical Trial
NCT03836482
Funding Statement
National Institutes of Health R43HL118792 (DAB). UL1TR00240 (HDH) Frankel Cardiovascular Center Inaugural Grant (HDH) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approved by University of Michigan's Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding sources: National Institutes of Health grants R43HL118792; UL1TR00240 Frankel Cardiovascular Center Inaugural grant, University of Michigan
Competing interests: HDH, DAB, AJW: Innovative Biotherapies, Inc.; SeaStar Medical, Inc.
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
